-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎The content team editor of WuXi AppTec recently, the World Health Organization (WHO) updated its COVID-19 patient care guidelines to include interleukin-6 (IL-6) receptor inhibitors
.
The results of a prospective and meta-study initiated by the WHO show that it can save the lives of patients with severe or critical COVID-19, especially when used with corticosteroids
.
This analysis included 27 clinical trials with more than 10,000 patients enrolled, making it the largest analysis of such drugs to date
.
The WHO press release stated that this is the first drug found to be effective against COVID-19 since the organization recommended corticosteroids in September 2020
.
WuXi AppTec's content team maps severe or critical COVID-19 patients who often have an overreaction of the immune system, which is very harmful to the patient's health
.
IL-6 inhibitors (such as tocilizumab and sarilumab) can suppress this overreaction
.
This data analysis shows that compared with standard treatment, the use of these drugs can reduce the chance of death by 13% in severe or critically ill patients
.
For critically ill patients, the number of deaths per 1,000 patients can be reduced by as much as 28
.
In addition, compared with standard treatment, severe and critically ill patients treated with IL-6 receptor inhibitors are 28% less likely to require mechanical ventilation
.
Clinical trial investigators in 28 countries shared data with WHO (including pre-publication data)
.
Researchers around the world have compiled and analyzed the data
.
The World Health Organization stated in a press release that with the support of these key partners, it will be able to quickly issue this trusted recommendation
.
Reference: [1] WHO recommends life-saving interleukin-6 receptor blockers for COVID-19 and urges producers to join efforts to rapidly increase access.
Retrieved July 7, 2021, from https:// item/06-07-2021-who-recommends-life-saving-interleukin-6-receptor-blockers-for-covid-19-and-urges-producers-to-join-efforts-to-rapidly-increase-access[ 2] Interleukin-6 Inhibitors.
Retrieved July 7, 2021, from https:// Note: This article aims to introduce medical and health research progress, not a treatment plan Recommended
.
If you need guidance on treatment plans, please go to a regular hospital for treatment
.
.
The results of a prospective and meta-study initiated by the WHO show that it can save the lives of patients with severe or critical COVID-19, especially when used with corticosteroids
.
This analysis included 27 clinical trials with more than 10,000 patients enrolled, making it the largest analysis of such drugs to date
.
The WHO press release stated that this is the first drug found to be effective against COVID-19 since the organization recommended corticosteroids in September 2020
.
WuXi AppTec's content team maps severe or critical COVID-19 patients who often have an overreaction of the immune system, which is very harmful to the patient's health
.
IL-6 inhibitors (such as tocilizumab and sarilumab) can suppress this overreaction
.
This data analysis shows that compared with standard treatment, the use of these drugs can reduce the chance of death by 13% in severe or critically ill patients
.
For critically ill patients, the number of deaths per 1,000 patients can be reduced by as much as 28
.
In addition, compared with standard treatment, severe and critically ill patients treated with IL-6 receptor inhibitors are 28% less likely to require mechanical ventilation
.
Clinical trial investigators in 28 countries shared data with WHO (including pre-publication data)
.
Researchers around the world have compiled and analyzed the data
.
The World Health Organization stated in a press release that with the support of these key partners, it will be able to quickly issue this trusted recommendation
.
Reference: [1] WHO recommends life-saving interleukin-6 receptor blockers for COVID-19 and urges producers to join efforts to rapidly increase access.
Retrieved July 7, 2021, from https:// item/06-07-2021-who-recommends-life-saving-interleukin-6-receptor-blockers-for-covid-19-and-urges-producers-to-join-efforts-to-rapidly-increase-access[ 2] Interleukin-6 Inhibitors.
Retrieved July 7, 2021, from https:// Note: This article aims to introduce medical and health research progress, not a treatment plan Recommended
.
If you need guidance on treatment plans, please go to a regular hospital for treatment
.
